Agile ($AGRX) Says It's On Track To Hit $25-$30M Net Annual Revenue After A Strong Performance In Q2

  • last year
Agile Therapeutics released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses. “We set single-quarter record highs in demand, net revenue, and factory sales, all while reporting another quarterly decrease in operating expenses,” Agile Chairperson and CEO Al Altomari said in a statement on the company’s second-quarter earnings. Here are the key highlights from the latest earnings release.

Recommended